| Literature DB >> 30718228 |
Janina Müller-Deile1,2, Heiko Schenk1,3, Philipp Niggemann1,3, Patricia Bolaños-Palmieri1,2, Beina Teng1,2, Alysha Higgs3, Lynne Staggs3, Hermann Haller1,3, Patricia Schroder3, Mario Schiffer4,2.
Abstract
Different glomerular diseases that affect podocyte homeostasis can clinically present as nephrotic syndrome with massive proteinuria, hypoalbuminemia, hyperlipidemia and edema. Up to now, no drugs that specifically target the actin cytoskeleton of podocytes are on the market and model systems for library screenings to develop anti-proteinuric drugs are of high interest. We developed a standardized proteinuria model in zebrafish using puromycin aminonucleoside (PAN) via treatment in the fish water to allow for further drug testing to develop anti-proteinuric drugs for the treatment of glomerular diseases. We noticed that fish that carry the nacre-mutation show a significantly higher susceptibility for the disruption of the glomerular filtration barrier following PAN treatment, which results in a more pronounced proteinuria phenotype. Nacre zebrafish inherit a mutation yielding a truncated version of microphthalmia-associated transcription factor/melanogenesis associated transcription factor (mitf). We hypothesized that the nacre mutation may lead to reduced formin expression and defects in cytoskeletal rearrangement. Based on the observations in zebrafish, we carried out a PAN treatment on cultured human podocytes after knockdown with MITF siRNA causing a rearrangement of the actin cytoskeleton.Entities:
Keywords: Glomerulopathy; MITF; PAN; Podocyte; Zebrafish
Year: 2019 PMID: 30718228 PMCID: PMC6451330 DOI: 10.1242/bio.040253
Source DB: PubMed Journal: Biol Open ISSN: 2046-6390 Impact factor: 2.422
Fig. 1.Influence of genetic background on the proteinuria phenotype. (A) Tg(l-fabp:eGFP-DBP) zebrafish backcrossed on homozygous for either the AB (AB fish) or the nacre (nacw2) background (nacre fish) as well as heterozygous zebrafish for nacre and AB background were treated with PAN at 46 h post-fertilization (hpf). Graph depicts max. fluorescence of circulating eGFP-DBP in the retinal vessel plexus of the fish eye 96 hpf. (B) Representative images of phenotypes of Tg(l-fabp:eGFP-DBP) zebrafish backcrossed on homozygous for either the AB (AB fish) or the nacre (nacw2) background (nacre fish) were treated with PAN (4 mg/ml) or DMSO at 46 hpf as indicated. Pictures were taken at 96 hpf. (C) Representative transmission electron microscopy images of the glomerular filtration barrier of Tg(l-fabp:eGFP-DBP) zebrafish backcrossed on homozygous for either the AB or the nacre (nacw2) background were treated with PAN (4 mg/ml) or DMSO at 46 hpf as indicated. Fish were collected at 120 hpf. Podocyte effacement after PAN treatment was more severe in nacre fish compared to AB fish. ***P<0.001, n.s., non-significant. Scale bars: (B) 500 μm, (C) 500 nm.
Fig. 2.Influence of NaHCO (A) Tg(l-fabp:eGFP-DBP) zebrafish backcrossed of nacre (nac) background were treated with PAN (4 mg/ml) or DMSO at 46–48 hpf in the presence of 0.045 g/l to 0.055 g/l NaHCO3. Graph depicts max. fluorescence of circulating eGFP-DBP in the retinal vessel plexus of the fish eye 96 hpf. n=23–24 per group. (B) Tg(l-fabp:eGFP-DBP) zebrafish backcrossed of nacre (nac) background were treated with PAN (4 mg/ml) or DMSO at either 46, 47 or 48 hpf. Graph depicts max. fluorescence of circulating eGFP-DBP in the retinal vessel plexus of the fish eye 96 hpf. n=21–23 per group. **P<0.01, ***P<0.005, ****P<0.001, n.s., non-significant.
Fig. 3.Dose response of PAN treatment and recovery following PAN treatment. (A) Tg(l-fabp:eGFP-DBP) zebrafish backcrossed on AB or nacre (nac) background were treated with 4 mg/ml, 6 mg/ml or 8 mg/ml PAN or DMSO at 46 hpf. Graph depicts max. fluorescence of circulating eGFP-DBP in the retinal vessel plexus of the fish eye 96 hpf. n=11–21 per group. (B) Tg(l-fabp:eGFP-DBP) zebrafish backcrossed on nacre (nac) background were treated with 4 mg/ml PAN at 46 hpf. Intensity of circulating eGFP-DBP (arbitrary units) in the retinal vessel plexus of the fish eye were measured at 96, 120, 144 and 168 hpf. n=19–21 per group. *P<0.05, ***P<0.005, ****P<0.001, n.s., non-significant.
Fig. 4.Mitf knockdown model and PAN treatment. (A) Phenotype pictures of Tg(l-fabp:eGFP-DBP) zebrafish backcrossed on AB background that were injected with either a mitf MO or a scrambled MO in a concentration of 250 µM in one to four-cell stage. Pictures were taken at 96 hpf. (B) Tg(l-fabp:eGFP-DBP) zebrafish backcrossed on AB background were injected with a mitf MO or a scrambled MO in a concentration of 250 µM in one to four-cell stage. At 46 hpf fish were treated either with PAN (4 mg/ml) or DMSO. Intensity of circulating eGFP-DBP (arbitrary units) in the retinal vessel plexus of the fish eye was measured at 96 hpf. Representative images of the fluorescence of circulating eGFP-DBP in the retinal vessel plexus of the fish eye 96 hpf are shown at the bottom. n=25–28 per group. (C) Q-PCR for inf2 mRNA expression in whole zebrafish at 120 hpf. Zebrafish (AB strain) were injected with CTRL-MO or a mitf-MO at one to four-cell stage. Data from three different experiments. Significance was tested with two-way ANOVA: **P<0.01, ****P<0.001, ns, non-significant. Scale bars: 500 µm.
Fig. 5.Mechanism of increased susceptibility to PAN treatment. (A) Immunofluorescence pictures of cultured human podocytes stained with Anti-Paxillin (green) and Phalloidin (red) to illustrate the cytoskeleton. Cells were either transfected with CTRL siRNA or a MITF siRNA and treated with DMSO or PAN 120 h after transfection. (B) Q-PCR for MITF mRNA (upper panel) and INF2 mRNA expression (lower panel) in cultured human podocytes. Cells were either transfected with CTRL siRNA, MITF siRNA or left untransfected. A reduced expression of MITF mRNA after MITFKD with siRNA was present. MITFKD induced a tendency to reduce INF2 mRNA expression compared to CTRL siRNA transfected cells. **P<0.01, n.s., non-significant. Scale bars: 50 µm.